-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Cube Info
Author: info
On May 5, the CDE official website showed that the clinical application for Orismilast sustained-release tablets jointly developed by Innovent Bio and UNION therapeutics was accepted by the State Food and Drug Administration
orismilast is a potent and highly selective next-generation PDE4 inhibitor with broad anti-inflammatory properties
In September 2021, Cinda and UNION reached an exclusive right to research, develop and commercialize orismilast in China (including mainland China, Hong Kong, Macau and Taiwan)
There are about 50 million patients with atopic dermatitis and 6 million patients with psoriasis in China, and the incidence shows a gradual upward trend with life>